ARQT
Arcutis Biotherapeutics, Inc.
ARQT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over ARQT overall, supported by stronger fundamentals and stronger modeled upside.
ARQT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
ARQT's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARQT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 41x | $27.53 | — |
| Cheap | 110x | $24.27 | -12% |
| Fair | 116x | $25.54 | -7.2% |
| Current | 125x | $27.53 | — |
| Expensive | 129x | $28.33 | +2.9% |
Historical ranges are pointers, not guarantees.
ARQT's PE is 125x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ARQT in the historical PE scenario, which offers more potential upside but is not a forecast.
ARQT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ARQT, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ARQT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | +206% |
| Q3 2026 | $0.22 | +$0.58 |
| Q2 2026 | $0.22 | +$0.97 |
| Q1 2026 | -$0.02 | +$1.02 |
| Q4 2025 | -$0.13 | +$1.03 |
| Q3 2025 | -$0.36 | +$1.29 |
| Q2 2025 | -$0.75 | +$1.30 |
| Q1 2025 | -$1.04 | +$1.75 |
| Q4 2024 | -$1.16 | +$2.62 |
ARQT has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ARQT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $143.9M | +45% |
| Q2 2026 | $129.9M | +59% |
| Q1 2026 | $105.4M | +60% |
| Q4 2025 | $129.5M | +81% |
| Q3 2025 | $99.2M | +122% |
| Q2 2025 | $81.5M | +164% |
| Q1 2025 | $65.8M | +33% |
| Q4 2024 | $71.4M | +428% |
ARQT has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.6% | -2 points |
| Q2 2026 | 13% | +31 points |
| Q1 2026 | -8.6% | +29 points |
| Q4 2025 | 14% | +25 points |
| Q3 2025 | 8.6% | +96 points |
| Q2 2025 | -18% | +144 points |
| Q1 2025 | -37% | +27 points |
| Q4 2024 | -11% | +442 points |
ARQT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ARQT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.8M | +$20.6M |
| Q2 2026 | $12.5M | +4974% |
| Q1 2026 | $2.2M | +$33.2M |
| Q4 2025 | $26.2M | +$26.9M |
| Q3 2025 | -$1.8M | +$33.1M |
| Q2 2025 | $246K | +$45.4M |
| Q1 2025 | -$31M | +$615K |
| Q4 2024 | -$748K | +$55.5M |
ARQT has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ARQT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +938K shares |
| 1 year | +7.7% | +9.8M shares |
| 3 years | +124% | +75.7M shares |
| 5 years | +189% | +89.6M shares |
| Available history | +259% | +98.7M shares |
ARQT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ARQT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | 12.5x | High |
| Q1 2024 | 0.1x | Very low |
| Q4 2023 | 0.8x | Very low |
| Q3 2023 | 0.7x | Very low |
ARQT's net debt is about 13 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ARQT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 48.9 | Neutral |
ARQT's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ARQT PE vs Healthcare Sector
| Metric | ARQT | Sector median | Relative |
|---|---|---|---|
| PE | 125x | 26x | 384% above |
ARQT is trading at 125x earnings, a 384% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ARQT on valuation relative to its sector.
ARQT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.0 | 1.6% below |
| 20 week MA | $26.7 | 3.2% above |
| 50 week MA | $25.7 | 7.2% above |
| 100 week MA | $21.0 | 31% above |
| 200 week MA | $15.0 | 84% above |
ARQT's trend is up, with a small recent dip: it's below only its 8-week average, and 84% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ARQT on trend strength, trading above more of its moving averages.
ARQT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.8 | $29.6 | +36% |
| 2021 | $29.6 | $20.1 | -32% |
| 2022 | $20.1 | $14.3 | -29% |
| 2023 | $14.3 | $3.23 | -77% |
| 2024 | $3.23 | $14.3 | +343% |
| 2025 | $14.3 | $29.0 | +103% |
| 2026 YTD | $29.0 | $27.5 | -5% |
ARQT's yearly returns have swung widely, from +343% in 2024 to −77% in 2023. It's down 5% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ARQT on returns for 2026, with the stronger performance.